AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

3.19M

Current Price

$0.09
+0.0000 (+0.0000%)

Book Price

$-0.23
Overvalued by 368.78%
Financial Institution

Company Metrics

  • 1.0378 P/E
  • 75.9637 P/S
  • 0.6167 P/B
  • 0.0820 EPS
  • 0.05 / N/A % Dividend
  • 38,236.00 Avg. Vol.
  • 37.49M Shares
  • 3.19M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Technical Insights on Affymax, Inc. (OTCMKTS: AFFY)
MicroCap Daily - Nov 3, 2014
Affymax, Inc. (OTCMKTS: AFFY) has been moving in a bearish trend since July, 2014 trading around $0.10 per share, but the stock did saw a major bullish rally in the months of January to April , 2014 when its touched its high of $1.04 at a trading ...
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
Yesterday's market session was a real disaster for Affymax, Inc. (OTCMKTS:AFFY, AFFY message board). Once the 8-K announcing that the partnership AFFY had with Takeda has been terminated affected the market, the company lost 54.55% of its share ...
Here is What Hedge Funds Think About Affymax, Inc. (AFFY)
Insider Monkey (blog) - Jun 10, 2013
Is Affymax, Inc. (NASDAQ:AFFY) a first-rate investment now? The smart money is taking a pessimistic view. The number of long hedge fund positions were cut by 4 recently.
Lawsuit on Behalf of Affymax, Inc. (AFFY) Investors Over Alleged Misleading ...
GlobeNewswire (press release) - Mar 4, 2013
SAN DIEGO, March 4, 2013 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of purchasers of Affymax, Inc. (AFFY) common stock during the period between December 8, 2011 and February 22, 2013 ...
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide ...
GlobeNewswire (press release) - Jul 18, 2013
NEW YORK, July 18, 2013 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of Telestone Technologies Corp.
Affymax, Inc.'s Pain Becomes Amgen Inc.'s Gain
iStockAnalyst (press release) - Feb 25, 2013
(By Mani) Affymax, Inc. (NASDAQ: AFFY) announced a national voluntary recall of all lots of Omontys after reports of serious hypersensitivity reactions including anaphylaxis.
Affymax stock plunges 85 percent on drug recall - Reuters
Down 85%! Why Affymax Is Getting Crushed This Morning - Motley Fool
Affymax Drops On Nasdaq Delisting And Criticism
Seeking Alpha - Jun 4, 2013
In February 2013, Affymax (NASDAQ: OTCPK:AFFY) made headlines after a nationwide voluntary recall of the erythropoietic agent OMONTYS (peginesatide) after reports of extreme hypersensitivity reactions to the drug, as well as five deaths that were ...
Hedge Funds Are Selling Affymax, Inc. (AFFY) - Northwest Biotherapeutics, Inc ...
Insider Monkey (blog) - Apr 8, 2013
When looking at the hedgies we track, OrbiMed Advisors, managed by Samuel Isaly, holds the most valuable position in Affymax, Inc. (NASDAQ:AFFY). OrbiMed Advisors has a $48.9 million position in the stock, comprising 1.5% of its 13F portfolio.
Q4 Omontys Sales Disappoint, Affymax Headed Lower
Seeking Alpha - Feb 6, 2013
Affymax's (OTCPK:AFFY) marketing partner Takeda announced weaker-than-expected sales for Omontys, Affmax's erythropoeitin stimulating agent (ESA) for dialysis patients.